Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$7.11 - $9.64 $361,600 - $490,271
-50,858 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$5.04 - $8.73 $256,324 - $443,990
50,858 New
50,858 $378,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Jasper Ridge Partners, L.P. Portfolio

Follow Jasper Ridge Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jasper Ridge Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Jasper Ridge Partners, L.P. with notifications on news.